A 144-patient, two-site German study that evaluated two different doses of psilocybin versus nicotinamide in patients with treatment-resistant depression (TRD), dubbed EPIsoDE, was published this month (Mertens et al., 2026). We covered an earlier abstract, which hinted at the results of the study, in Bulletin 220. Prior to that, we first highlighted the study’s design and a glimpse at the…


